Xylem (XYL) Stock Forecast & Price Target

Xylem has demonstrated a robust financial performance with 3Q25 sales reaching $656.0 million, reflecting a 5.3% year-over-year increase largely attributed to growth in the treatment segment. The company has shown continued organic revenue growth, achieving a 7% increase driven by strong demand and successful backlog execution, which has effectively countered anticipated challenges. Furthermore, the integration of Evoqua is anticipated to enhance growth further, contributing to Xylem's prospects for continued margin expansion and overall operational improvement moving forward.

Xylem's financial outlook is negatively impacted by a combination of factors, including a slight EPS guidance miss for 2026 and ongoing softness in the Chinese market, which is expected to exert pressure on revenue in the first half of 2026. The company's 80/20 rationalization efforts and deferred project timelines, particularly in the Utility and Applied Water segments, indicate a slow start to the year, further complicating growth prospects in critical markets. Additionally, a projected decline in first-quarter revenue, alongside anticipated decreases in EBITDA margins, reflects the challenges Xylem faces as it navigates external economic pressures and competitive dynamics.